<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36881098</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7549</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>In vivo (Athens, Greece)</Title><ISOAbbreviation>In Vivo</ISOAbbreviation></Journal><ArticleTitle>Insulin Docking Within the Open Hemichannel of Connexin 43 May Reduce Risk of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>547</EndPage><MedlinePgn>539-547</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21873/invivo.13112</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Type 2 diabetes (T2D), characterized by hyperinsulinemia, protects motor neurons against amyotrophic lateral sclerosis (ALS). Type 1 diabetes and a total lack of insulin are associated with increased risk of ALS. Connexin 43 (Cx43), an astrocyte protein, operates as an open pore via which toxic substances from the astrocytes reach motor neurons.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In the current study, we performed molecular docking of insulin with monomeric Cx31, monomeric Cx43, and hexameric Cx31 to assess whether insulin might affect the pore. Hexameric Cx31 and hexameric Cx43 are transmembrane hemichannels composed of 6 subunits; they bind together to form gap junction intercellular channels. We used the program AutoDock Vina Extended for the molecular docking study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cx31 shares amino acid and structural similarity to Cx43, and insulin docks to the same position at the N-terminal domain of monomeric Cx31 and monomeric Cx43. Insulin docks within the open hemichannel of hexameric Cx31, potentially blocking it. Molecular dynamics simulation shows that the block is highly stable and may be responsible for the protective effect of T2D on ALS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Insulin, especially intranasal insulin, might be a treatment for ALS. An insulin secretogogue such as oral sulfonylurea or meglitinide might also be of value.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lehrer</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fermata Pharma, New York, NY, U.S.A.; steven@fermatapharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rheinstein</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Severn Health Solutions, Severna Park, MD, U.S.A.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>In Vivo</MedlineTA><NlmUniqueID>8806809</NlmUniqueID><ISSNLinking>0258-851X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018031">Connexin 43</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018031" MajorTopicYN="N">Connexin 43</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">insulin</Keyword></KeywordList><CoiStatement>The Authors have no conflicts of interest to declare in relation to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36881098</ArticleId><ArticleId IdType="pmc">PMC10026685</ArticleId><ArticleId IdType="doi">10.21873/invivo.13112</ArticleId><ArticleId IdType="pii">37/2/539</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72(8):905&#x2013;911. doi: 10.1001/jamaneurol.2015.0910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0910</ArticleId><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22(11):1436&#x2013;1442. doi: 10.1111/ene.12632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12632</ArticleId><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F, d&#x2019;Errico A, Carn&#xe0; P, Calvo A, Costa G, Chi&#xf2; A. The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol. 2018;25(1):164&#x2013;170. doi: 10.1111/ene.13465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13465</ArticleId><ArticleId IdType="pubmed">28921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tang L, Huang T, Fan D. Association between type 2 diabetes and amyotrophic lateral sclerosis. Sci Rep. 2022;12(1):2544. doi: 10.1038/s41598-022-06463-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-06463-6</ArticleId><ArticleId IdType="pmc">PMC8847454</ArticleId><ArticleId IdType="pubmed">35169211</ArticleId></ArticleIdList></Reference><Reference><Citation>Almad AA, Taga A, Joseph J, Gross SK, Welsh C, Patankar A, Richard JP, Rust K, Pokharel A, Plott C, Lillo M, Dastgheyb R, Eggan K, Haughey N, Contreras JE, Maragakis NJ. Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS. Proc Natl Acad Sci U.S.A. 2022;119(13):e2107391119. doi: 10.1073/pnas.2107391119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2107391119</ArticleId><ArticleId IdType="pmc">PMC9060483</ArticleId><ArticleId IdType="pubmed">35312356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawat G, Baroudi G. Connexin 43 hemichannels and pharmacotherapy of myocardial ischemia injury. Novel Strategies in Ischemic Heart. 2016;Disease:189&#x2013;218. doi: 10.5772/32201.</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/32201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Jeong H, Hyun J, Ryu B, Park K, Lim HH, Yoo J, Woo JS. Cryo-EM structure of human Cx31.3/GJC3 connexin hemichannel. Sci Adv. 2020;6(35):eaba4996. doi: 10.1126/sciadv.aba4996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aba4996</ArticleId><ArticleId IdType="pmc">PMC7455182</ArticleId><ArticleId IdType="pubmed">32923625</ArticleId></ArticleIdList></Reference><Reference><Citation>Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes. 2000;49(12):2094&#x2013;2101. doi: 10.2337/diabetes.49.12.2094.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.49.12.2094</ArticleId><ArticleId IdType="pubmed">11118012</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455&#x2013;461. doi: 10.1002/jcc.21334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21334</ArticleId><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera&#x2014;a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605&#x2013;1612. doi: 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, &#x17d;&#xed;dek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583&#x2013;589. doi: 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL. Breakthrough discovery in protein structure prediction and the promise of new treatments. JAMA. 2021;326(14):1369&#x2013;1370. doi: 10.1001/jama.2021.15728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15728</ArticleId><ArticleId IdType="pubmed">34554183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, Beglov D, Vajda S. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12(2):255&#x2013;278. doi: 10.1038/nprot.2016.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.169</ArticleId><ArticleId IdType="pmc">PMC5540229</ArticleId><ArticleId IdType="pubmed">28079879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozakov D, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR, Vajda S. How good is automated protein docking. Proteins. 2013;81(12):2159&#x2013;2166. doi: 10.1002/prot.24403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.24403</ArticleId><ArticleId IdType="pmc">PMC3934018</ArticleId><ArticleId IdType="pubmed">23996272</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E, Gorter JA, Jansen GH, Leenstra S, Yankaya B, Troost D. Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol. 2001;101(5):449&#x2013;459. doi: 10.1007/s004010000305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010000305</ArticleId><ArticleId IdType="pubmed">11484816</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi C, Acosta-Gutierrez S, Lavriha P, Othman A, Lopez-Pigozzi D, Bayraktar E, Schuster D, Picotti P, Zamboni N, Bortolozzi M. Structure of the connexin-43 gap junction channel reveals a closed sieve-like molecular gate. , 2022. DOI: . bioRxiv. 2022 doi: 10.1101/2022.03.26.485947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.26.485947</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouche C, Lopez X, Fleischman A, Cypess AM, O&#x2019;Shea S, Stefanovski D, Bergman RN, Rogatsky E, Stein DT, Kahn CR, Kulkarni RN, Goldfine AB. Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci U.S.A. 2010;107(10):4770&#x2013;4775. doi: 10.1073/pnas.1000002107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1000002107</ArticleId><ArticleId IdType="pmc">PMC2842068</ArticleId><ArticleId IdType="pubmed">20176932</ArticleId></ArticleIdList></Reference><Reference><Citation>Born J, Lange T, Kern W, Mcgregor G, Bickel U, Fehm H. Sniffing neuropeptides: a transnasal approach to the human brain. Nature Neuroscience. 2021;5(6):514&#x2013;516. doi: 10.1038/nn0602-849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn0602-849</ArticleId><ArticleId IdType="pubmed">11992114</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer&#x2019;s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50(1):164&#x2013;168. doi: 10.1212/wnl.50.1.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.50.1.164</ArticleId><ArticleId IdType="pubmed">9443474</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallschmid M. Intranasal insulin. J Neuroendocrinol. 2021;33(4):e12934. doi: 10.1111/jne.12934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jne.12934</ArticleId><ArticleId IdType="pubmed">33506526</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, You Q, Shu J, Gang Q, Jin H, Yu M, Sun W, Zhang W, Huang Y. GJA1 gene polymorphisms and topographic distribution of Cranial MRI lesions in cerebral small vessel Disease. Front Neurol. 2020;11:583974. doi: 10.3389/fneur.2020.583974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.583974</ArticleId><ArticleId IdType="pmc">PMC7723976</ArticleId><ArticleId IdType="pubmed">33324328</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine C, Laroussi N, Mkaouar R, Jouini R, Khayat O, Redissi A, Mosbah A, Dallali H, Chedly Debbiche A, Zaouak A, Fenniche S, Abdelhak S, Hammami-Ghorbel H. Expanding the clinical phenotype associated with NIPAL4 mutation: Study of a Tunisian consanguineous family with erythrokeratodermia variabilis-Like Autosomal Recessive Congenital Ichthyosis. PLoS One. 2021;16(10):e0258777. doi: 10.1371/journal.pone.0258777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0258777</ArticleId><ArticleId IdType="pmc">PMC8528321</ArticleId><ArticleId IdType="pubmed">34669720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>